- Global Pharma News & Resources

Genixus™ Expands Manufacturing Capacity to Meet Demand for KinetiX™ RTA Syringes

- Adds 30,000+ sq. ft. for manufacturing, warehousing, and distribution

- New facility includes automated syringe production, isolators, and clean rooms

- Plans to triple workforce by Q4 2024 to match demands of capacity increase

KANNAPOLIS, N.C.--(BUSINESS WIRE)--Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, today announced it is finalizing the buildout of a new manufacturing site in Concord, N.C., complete with automated manufacturing and cutting edge technology to support the KinetiX syringe platform and expanding portfolio.

The added manufacturing capacity is in response to the marketplace demand for ready-to-administer (RTA) syringes. Production of the company’s first product, KinetiX™ RTA Propofol, began at the company’s headquarters in Kannapolis and will expand into the new Concord facility. Genixus also plans to triple their staff by the end of 2024 in line with the expansion, while holding an option for incremental space as demand unfolds.

“The finalized fit out, featuring new state-of-the-art syringe production and isolators, significantly expands our production and will play a pivotal role in addressing the demand for Propofol and our launch of additional KinetiX products in the second half of 2023,” said Kendall Foster, Founder & Chief Executive Officer of Genixus.

The more than 30,000 sq. ft. expansion follows on the heels of delivering the company’s first product: KinetiX RTA Propofol, available in 10ml and 20ml sizes. The new buildout includes clean rooms for formulation, filling, inspection, and packaging, in addition to quality control labs and dedicated utilities.

“We are passionate about simplifying injectable medications so clinicians can increase their focus on patient care,” said Seth Coombs, Co-Founder & Chief Commercial Officer of Genixus. “The Concord manufacturing facility increases capacity for portfolio expansion within the KinetiX platform of injectables, allowing further solutions to be realized for the acute and critical care settings.”

RTA injectable medications are recommended whenever possible by the Joint Commission medication management standards. Genixus designed the new KinetiX Propofol RTA syringe to simplify workflow and support effective care delivery. KinetiX Propofol features several key attributes:

  • Long-term shelf stability to support a hospital’s supply chain
  • Intuitive labeling and color-coded plunger rod support rapid identification
  • Auto-dispensing cabinet (ADC) ready to keep product proximal to delivery site
  • RFID-enabled with the latest technology in kit and tray management
  • 10ml and 20ml RTA syringes offer flexibility to minimize waste
  • Novel durable polymer syringe eliminates risks of glass breakage and delamination

About Genixus

Genixus, headquartered in Kannapolis, North Carolina, is a development stage pharmaceutical manufacturer and FDA-registered repackager and 503B outsourcing provider of high-quality, easy-to-use, ready-to-administer products for acute and critical care. Leveraging the highest-quality biopharmaceutical manufacturing standards and innovative point-of-care design, Genixus is changing care delivery and helping healthcare professionals to achieve better quality outcomes for patients. For more information, visit and follow the company on LinkedIn.


Peter Collins
Gartman PR
(908) 499-1200

Editor Details

  • Company:
    • Businesswire
Last Updated: 07-Mar-2023